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Purpose: Transforming growth factor beta receptor II (TGFBR2) gene mutations are associated with Marfan syndrome;
however, the relationship between the mutations and clinical phenotypes are not clear.
Methods: Genomic DNA from peripheral blood leukocytes of a Chinese proband with Marfan syndrome, five of the
proband’s relatives, and 100 unrelated Chinese control subjects were isolated and screened for fibrillin-1 (FBN1) and
TGFBR2 gene mutations by direct sequencing, and a genotype-phenotype study was performed following a review of the
literature on TGFBR2 mutations in the search area. Also, the structure of TGFBR2 protein before and after gene mutation
was analyzed.
Results: The results identified a novel missense TGFBR2 mutation p.V453E (c.1358T>A) in the proband and two relatives
that was located in the F-helix in the kinase domain of TGFBR2. No such genetic change was observed in the unrelated
controls. No FBN1 mutation was detected in any of the subjects. Genotype-phenotype analyses indicated that F-helix
mutations are related to type 2 Marfan syndrome and Loeys-Dietz syndrome, and these mutations can lead to severe
cardiovascular (93.8%) and skeletal (81.3%) lesions and minor ocular lesions (25%). Losartan treatment can slow-down
the progression of aortic lesions.
Conclusions: The ﬁndings extend the mutation spectrum of Marfan syndrome, and that mutations at the F-helix in the
kinase domain of TGFBR2 may be associated with the development of severe cardiovascular and skeletal lesions and
minor ocular lesions. These findings have implications for genetic testing, diagnosis, and treatment in individuals with
transforming growth factor beta (TGF-β) signaling-related disorders.
Marfan  syndrome  (MFS)  is  an  autosomal  dominant
extracellular  connective  tissue  disorder  that  is  clinically
diagnosed according to the Ghent criteria [1]. Classic MFS
presents  as  abnormal  features  in  skeletal,  ocular,  and
cardiovascular systems. The skeletal abnormalities of affected
individuals typically include tall stature, long slender limbs
(dolichostenomelia),  scoliosis,  arachnodactyly,  and  pectus
excavatum or carinatum. About 80% of MFS sufferers have
ectopia lentis, which is almost always bilateral. Progressive
dilatation of the aorta is the main cardiovascular irregularity
of MFS individuals, and acute aortic dissection originating
from dilation of the ascending aorta is the leading cause of
premature  death  in  untreated  MFS  individuals  [2].  Other
manifestations, including spontaneous pneumothorax, apical
blebs, striae atrophicae, and lumbosacral dural ectasia, can
also be observed in MFS patients [3,4].
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MFS is most commonly caused by fibrillin-1 (FBN1)
gene mutations at chromosome 15q21.1, with the mutation
types  being  point  mutations,  insertions,  large  and  small
deletions, and splice mutations. The mutations are spread
throughout  almost  the  entire  FBN1  gene  without  obvious
predilection for any given region. Recent studies show that
genetic  heterogeneity  exists  in  MFS  individuals,  and
transforming growth factor beta receptor II (TGFBR2) gene
mutations have been identified in a subset of patients with
MFS – which was termed as type 2 Marfan syndrome (MFS2)
[5]. Mutations in TGFBR2 have also recently been identiﬁed
in patients with Loeys-Dietz syndrome, and familial thoracic
aortic aneurysms [6,7].
Transforming growth factor beta superfamily signaling is
of great importance in the maintenance of the extracellular
matrix and tissue homeostasis [8]. One important member of
this  gene  superfamily  is  TGFBR2,  which  encodes  for  the
trans-membrane  kinase  receptor  involved  in  signal
transduction of the transforming growth factor beta (TGF-β)
family of ligands [9]. This gene is composed of seven exons
encoding 567 amino acids to form an NH2-terminal ligand
binding  domain,  a  trans-membrane  region,  and  a
constitutively active COOH-terminal serine/threonine kinase
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55domain [10]. These structures are critical for TGF-β signaling,
which plays a key role in normal extracellular connective
tissue  functions.  Several  TGFBR2  mutations  have  been
reported  in  association  with  vascular  abnormalities  [5,
11-13], with most being missense substitutions or nonsense
mutations in the penultimate or ﬁnal exons and predicted to
disrupt  the  kinase  domain.  At  present  no  strict  genotype-
phenotype  correlations  between  TGFBR2  mutations  and
MFS2 have been established, and great clinical variability of
cardiovascular,  skeletal,  and  ocular  system  manifestations
exists among TGFBR2 mutation carriers.
This study describes the genetic and clinical features of
a Chinese family, the proband of which displays the MFS2
phenotype genetically caused by mutation at the TGFBR2
locus. A literature review was also undertaken with the aim
of exploring the relationship between mutations at the region
in this study and clinical phenotypes.
METHODS
Study subjects: This study was conducted in accordance with
the  Declaration  of  Helsinki  and  approved  by  the  Fuwai
Cardiovascular Center Ethics Committee.
An MFS patient and family and 100 unrelated controls
participated in this study. All subjects were of Han Chinese
origin.  Written  informed  consent  was  obtained  from  all
Figure 1. Family pedigree. The proband (III: 2, mutation carrier)
presented with an ascending aortic aneurysm and underwent a ROSS
procedure. Both the proband’s mother (II: 1) and uncle (II: 2) carry
a TGFBR2 mutation and have cardiovascular and skeletal system
irregularities. The proband’s grandfather (I: 1) died suddenly at 43
years of age from an ascending aortic dissection; however, no genetic
test was performed. No mutation was found in III: 1 and III: 3 who
have normal phenotypes.
subjects (or their parents if the subject was less than 18 years
of age).
The pedigree of the enrolled family is presented in Figure
1.  The  proband  of  the  enrolled  family  was  a  12-year-old
female (III: 2, in Figure 1), who presented for examination of
her  cardiovascular  system  because  previous  X-ray  results
indicated aortic root dilation. Other family members (II: 1, II:
2, II: 3, III: 1, III: 3, in Figure 1) of the proband were recruited
and  underwent  multidisciplinary  clinical  and  noninvasive
instrumental  studies.  Our  assessments  covered  all  the
diagnostic criteria for MFS [5]. A physical examination and
echocardiography were performed on the unrelated control
subjects to exclude MFS and other congenital abnormalities.
The aortic root diameter was evaluated by echocardiography.
Genetic analysis: Genomic DNA was isolated from peripheral
venous blood leukocytes of all subjects using a commercially
available  kit  (Qiagen  Inc.,  Germantown,  MD).  Following
amplification  by  polymerase  chain  reaction  (35  cycles),
mutation screening (which allowed for the scanning of 65
FBN1 exons and flanking regions, including the splice sites
up to the branching regions [primers used for bidirectional
sequencing are presented in Appendix 1]) was performed
using an ABI3730xl Sequencer (Applied Biosystems, Foster
City, CA). The primers used for bidirectional sequencing of
TGFBR2  are  presented  in  Table  1.  TGFBR2  mutation
screening of all seven encoding exons was performed after
finding that all the exon-intron boundaries of FBN1 were
negative. Mutation numbering refers to the TGFBR2 cDNA
GenBank reference sequence: NM_003242.5, with the A of
the ATG translation initiation codon as nucleotide +1.
In  silico  prediction  of  the  effects  caused  by  TGFBR2
mutations:  The  human  TGFBR2  reference  sequence
accession  NP_003233.4  was  used  to  perform  in  silico
prediction, and the SWISS-MODEL tool was used [14,15].
Mutagenesis and visualization were performed to determine
the possible effects of the mutation on the structure of their
corresponding modules during in silico 3D modeling analysis.
Genotype-phenotype  investigation:  A  literature  search  of
TGFBR2 mutations and related clinical manifestations was
performed and mutations were classified according to their
locations in the gene and functional domains. Correlations
between mutations at the region where the mutation in this
study was found and their clinical features were analyzed.
Statistical analysis: Statistical analyses were performed using
SPSS  software  version  15.0  (SPSS  Inc.,  Chicago,  IL).
Phenotypes detected which involved separate organ systems
were compared with the Pearson χ2 test; or using a Fisher’s
exact test for small samples. All the reported p values are two-
sided, and a p value of <0.05 was considered significant.
RESULTS
Clinical features of the patients: The clinical manifestations
of  all  family  members  are  summarized  in  Table  2.  The
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56proband was confirmed as an MFS patient [5], and a familial
history suggestive of MFS was reported. A chest computed
tomography of the proband revealed that she had an ascending
aortic aneurysm, and echocardiography showed an aortic root
diameter of 50 mm. The patient underwent a ROSS procedure
(graft replacement of the ascending aorta) to treat her aortic
aneurysm.  A  characteristic  habitus  with  tall  stature,  long
slender limbs (dolichostenomelia) was observed. She was 168
cm tall at 12 years of age, and her arm span to height ratio was
1.15. Pectus carinatum, scoliosis (25°), dolichostenomelia,
arachnodactyly, and positive wrist and thumb signs were also
noted; the findings indicated that her skeletal system was
involved. Striae atrophicae was also found.
The proband’s mother had a characteristic habitus with
tall stature and long slender limbs (arm span to height ratio
was 1.09); dolichostenomelia, arachnodactyly, and wrist and
thumb signs were noted; and dilatation of the ascending aorta
(aortic root diameter was 45 mm) and aortic regurgitation
were observed.
No ocular lesions were found in either the proband or her
mother.
Further  findings  positive  for  MFS  in  other  family
members are presented in Table 2. No positive findings were
detected in the control subjects.
Losartan (25 mg per day) was used as previously reported
[16] in the proband after surgery to prevent aortic enlargement
and  associated  cardiovascular  pathologic  changes,  and  no
recurrent aortic lesion was found after losartan treatment.
Losartan  (50  mg  per  day)  was  also  used  in  the  other
individuals (II: 1 and II: 2) who had TGFBR2 mutations. No
obvious progression of aortic root dilation was detected after
losartan therapy.
Mutation analysis: A novel missense mutation (p.V453E (c.
1358T>A)  in  exon  5)  was  identified  in  TGFBR2  in  the
proband  (III:  2),  the  proband’s  mother  (II:  2),  and  the
proband’s uncle (II: 1; see Figure 2). This alteration was not
detected in the 100 unrelated chromosomes from ethnically
matched Han Chinese controls.
The  mutation  identified  affects  a  highly  conserved
nucleotide and is predicted as damaging protein production or
affecting protein function. The mutation located in the F-helix
in the kinase domain of TGFBR2, which was formed by the
440–457 residues encoded by the 1318–1370 base pairs.
No FBN1 mutation was found in any of the subjects of
the study.
Protein structure changes due to mutations: The missense
mutation involves a highly conserved valine residue that is
TABLE 1. PRIMERS USED FOR THE AMPLIFICATION OF TGFBR2.
Exon Forward primer ( 5’→ 3’) Reverse primer ( 5’→ 3’) Melting
temperature
(°C)
Product
  length
(bp)
Exon1 AGCTGTTGGCGAGGAGTTTCCTGTTT GCCGCCTTCAGATAACCAACTTCTCAAAC 58 765
Exon2 TTGACAAAAGCAAATGGCTACTC GGAAAGGGAAATGGAACAGG 58 539
Exon3 AAACAGAAAAGAGTAGAAAAGCATAGG TGATGAGAACCAGAACAAACCCT 58 574
Exon4 AGCAGGGGATGACGAACAGA GAAGGATTTGAAGATAGGAGGAGAA 58 1226
Exon5 TGTTTATGGTCTTTAGAGGGTTTTC CCAAATAGTTCTGGGATGGTTGTA 58 507
Exon6 AAAACCTAAGCTCCGTGAC TTAACAGGGCCATAGAACA 58 545
Exon7 GTGTTGGGAGTGTTAGTGTA CAATGTCAAAGGCATAGAAT 58 695
          Sequences are given in the 5’→ 3’direction. TGFBR2: transforming growth factor beta receptor II gene.
TABLE 2. CLINICAL MANIFESTATION OF THE PROBAND AND HER FAMILY MEMBERS.
Parameters III:2 II:2 II:1 I:1
Age 12 35 39 Death at 43
Sex Female Female Male Male
Cardiovascular system Aortic root dilation (aortic root
diameter=50 mm); Aortic
regurgitation; Mitral valve
regurgitation; Dilatation of the main
pulmonary artery.
Aortic root dilation (aortic root
diameter=45 mm); Aortic
regurgitation.
Aortic root dilation (aortic root
diameter=48 mm)
Aortic root dilation;
Dissection of the
ascending aorta
Skeletal system Arm span to height ratio=1.15; Wrist
and thumb signs; Scoliosis of=25°;
Pectus excavatum; Dolichostenomelia;
Arachnodactyly.
Arm span to height ratio=1.09;
Dolichostenomelia;
Arachnodactyly; Wrist and
thumb signs.
Arm span to height ratio=1.05;
Dolichostenomelia;
Arachnodactyly; Joint
hypermobility.
?
Ocular system Nil Nil Nil ?
Pulmonary system Nil Nil Nil ?
Skin and integument Striae atrophicae Nil Nil ?
Ghent nosology Fulflled Not fulflled Not fulflled ?
TGFBR2 mutation c.1358T>A, p.V453E c.1358T>A, p.V453E c.1358T>A, p.V453E ?
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57located in the F-helix in the kinase domain of TGFBR2. The
F-helix  in  the  kinase  domain  plays  an  important  role  in
maintaining the function of TGFBR2. The mutant residue is
predicted to induce steric clashes with its surroundings. In
silico modeling analysis showed that four additional hydrogen
bonds were formed; and the conformation changed after the
valine residue was replaced by glutamic acid (Figure 3E,F).
This  structural  alteration  may  perturb  the  crucial  F-helix
structural  components  of  the  protein  kinase  domain.
Previously reported mutations at the F-helix can alter the
protein kinase domain of TGFBR2 to impair the TGFBR2
pathway (Figure 3C,D), and can therefore lead to MFS or
MFS-like phenotypes [17].
Genotype-phenotype  relationships:  The  results  of  the
literature  review  of  the  F-helix  of  the  kinase  domain  of
TGFBR2 are shown in Table 3. Nine kinds of mutations (all
of which are point mutations, except for one deletion change)
were found in this domain, as reported in 16 studies [5,12,
13,18-25].  Almost  all  mutation  carriers  (15/16,  93.8%)
displayed major cardiovascular system abnormalities. Four
cases (4/16, 25%) were reported as showing minor ocular
lesions, and no ectopia lentis was reported. Skeletal system
abnormalities were reported in 81.3% (13/16) of cases, and
31.3%  (5/16)  had  major  skeletal  system  lesions.  The
cardiovascular and skeletal system had significantly higher
involvement  rates  when  compared  to  the  ocular  system
(p<0.01 of both compares), but no significant difference in
involvement  rates  was  found  between  the  cardiovascular
system and the skeletal system (93.8% versus 81.3%, p=0.60).
MFS2  was  reported  in  37.5%  (6/16  cases)  of  all  the
patients,  but  only  12.5%  (2/16  cases)  fulfilled  the  Ghent
nosology  criteria.  The  remaining  62.5%  are  Loeys-Dietz
Syndrome individuals. The occurrence rates of MFS2 and
Loeys-Dietz Syndrome caused by mutations in this region
were comparable (p=0.29). Mutations in this region tend to
attack the carriers before adulthood, and a significant higher
illness detection rate was found in patients <16 years old
(p=0.012).
DISCUSSION
Marfan syndrome is an autosomal dominant connective tissue
disorder  involving  multiple  organ  systems.  Patients  with
Figure 2. Sequencing plots of TGFBR2.
A  novel  heterozygous  missense
mutation  of  TGFBR2  (c.1358T>A,
p.V453E)  affecting  an  evolutionarily
conserved amino acid was detected in
the proband (III: 2), her mother (II: 1)
and  uncle  (II:  2).  The  mutation  was
absent in other family members (III: 1,
III: 3, II: 3) and the controls.
Figure  3.  Prediction  of  the  impact  of
mutations at the F-helix in the kinase
domain  of  TGFBR2.  A:  Three-
dimensional  plot  of  normal  TGFBR2
drawn  with  Swiss-Pdb  Viewer.  B:
Ramachandran  plot  of  predicted
p.V453E. Phi and Psi angles changed
after mutation. C and D: The normal and
mutant residues at this region. E and F:
The structure change after the normal
hydrophobic  valine  residue  was
replaced the by a hydrophilic glutamic
acid.
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59young-onset cardiovascular lesions failing to meet the Ghent
criteria have been classiﬁed as Marfan-like connective tissue
disorders. After the first report by Boileau et al. [26] in 1993,
a Marfan-like phenotype that was not linked to the FBN1
mutation was subsequently designated Marfan syndrome type
2  (MFS2).  Diagnosis  of  MFS2  consists  of  severe
cardiovascular ﬁndings, which can include the sudden death
of affected people at a young age owing to a thoracic aortic
dissection,  and  typical  MFS  skeletal  features,  but  ocular
ﬁndings were rare [27]. Genetic analysis of MFS2 patients by
Mizuguchi  et  al.  [5]  identified  a  de  novo  chromosomal
rearrangement involving chromosome 3p24.1 that can disrupt
TGFBR2  function  to  result  in  protein  truncation  due  to
abnormal splicing. Further studies demonstrate that the MFS2
phenotype is caused by mutations in TGFBR2.
TGF-β  family  cytokines  form  a  complex  signaling
pathway and control several cellular processes, including cell
proliferation and differentiation, apoptosis, and extracellular
matrix formation [28]. Incorrect TGF-β signaling may lead to
a decreased and disordered incorporation of fibrillin into the
connective tissue matrix, and this abnormality in turn results
in  human  MFS  phenotypes  [29].  Two  types  of  trans-
membrane  receptors,  type  I  (TbRI)  and  type  II  (TbRII),
transduce the signals of TGF-β into the cell. TbRI and TbRII
are encoded by TGFBR1 and TGFBR2, respectively [30,31].
The  identification  of  TGFBR2  mutations  in  patients  with
MFS2  provided  the  ﬁrst  direct  link  between  a  human
connective tissue disorder and abnormal TGF-β signaling.
TGFBR2 mutations may cause a loss in function of TbRII and
lead  to  MFS2,  Loeys-Dietz  Syndrome  [32]  and  Type  2
Thoracic aortic aneurysms and dissections.
In the present study we directly sequenced the entire
coding region of FBN1 and TGFBR2, and found a previously
unreported TGFBR2 mutation, p.V453E (c.1358T>A). V453
is a highly conserved residue located in the F-helix in the
kinase domain of TbRII. The F-helix functions as a scaffold
to correctly position catalytic, substrate-binding, and substrate
residues [33]. The D-helix in the protein kinase domain is
either close to or makes direct contact with the substrate.
Mutations  at  the  F-helix  will  perturb  F-helix-D-helix
communication and impair TGFBR2 signaling. In this study,
the V453E mutation replaced the hydrophobic valine with a
hydrophilic  glutamic  acid  to  form  more  hydrogen  bonds,
which altered the conformation of the F-helix (Figure 3E,F).
This alteration destabilized the F-helix, which in turn perturbs
the protein structure and function of TGFBR2. Therefore, the
newly identified p.V453E missense mutation could seriously
disturb the TGF-β signaling pathway, the consequence of
which is MFS2 phenotypes in affected individuals. These
findings aid in understanding that MFS can be caused not only
by mutations in FBN1 but also by mutations in TGFBR2.
More  research  is  needed  to  better  understand  the
relationship  between  TGFBR2  mutations  and  MFS2
phenotypes. Great clinical heterogeneity was observed among
TGFBR2 mutations carriers [34]. In the present study, we
found that F-helix mutation carriers had a very high major
cardiovascular  system  involvement  rate  (93.8%).  TGF-β
signaling drives aneurysm progression in MFS. Habashi et al.
[35] and Holm et al. [36] found that an angiotensin II receptor
blocker, losartan, can inhibit TGF-β-mediated activation of
extracellular signal–regulated kinase. Therefore, losartan can
be widely used to treat patients with MFS. In our study, no
obvious progression of aortic lesion was observed in all of the
affected individuals after losartan treatment.
The  proband  with  a  TGFBR2  mutation  fulfilled  the
current  diagnostic  criteria  of  MFS2  [22],  indicating  an
association between the genotype of V453E alterations and
MFS2. Nine kinds of mutations at the F-helix of TGFBR2
have been reported, with residue sites 446 and 449 having
higher mutation frequencies. Patients with mutations at this
region are more prone to severe cardiovascular events and
skeletal lesions (Table 3). Because mutations at the F-helix
can  seriously  impair  the  TGF-β  signaling  pathway,
individuals who have mutations at this region display a higher
ratio (p=0.012) of developing severe clinical manifestations
before adulthood.
Previous studies indicate that ectopia lentis is rare in
MFS2 individuals [5,18], and a study performed in Chinese
patients with Marfan-related disorders also found no ocular
involvement [32]. In the Hilhorst-Hofstee et al. [37] study,
they  thought  that  ectopia  lentis  is  caused  by  the  lower
production of ﬁbrillin-1 and not by perturbation of the TGF-
β  signaling.  Consistent  with  these  results,  no  ocular
involvement was observed in patients of our study who had
TGFBR2  mutations,  and  no  ectopia  lentis  was  found  in
patients carrying a mutation at the F-helix. Only four F-helix
mutation carriers (4/16, 25%) were reported as showing minor
ocular lesions. One MFS2 patients had myopia, and in the
three patients with Loeys-Dietz Syndrome, two blue sclerae
and two strabismus were reported (Table 3).
In  conclusion,  this  study  reports  a  novel  TGFBR2
mutation in a Chinese family with a MFS2 proband. Mutations
at the F-helix in the kinase domain of TGFBR2 are prone to
developing  severe  cardiovascular  phenotypes  and  skeletal
irregularities.  Losartan  can  slow-down  the  progression  of
aortic  lesion.  Mutations  in  this  region  are  also  related  to
young-onset clinical phenotypes. Minor ocular abnormalities
can be found in a low percentage of carriers with mutation at
the  F-helix.  These  findings  have  implications  for  genetic
testing, diagnosis, and treatment in individuals with MFS2,
and other TGF-β signaling-related disorders.
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62Appendix 1
Primers used for the amplification of FBN1. To access
the data, click or select the words “Appendix 1.” This will
initiate  the  download  of  a  compressed  (pdf)  archive  that
contains the file.
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